The clinical implications of our study are that there is likely a molecular basis for differences in bladder fibrosis observed between males and females and that pharmacologic approaches to modulate NKX3.1 in prostate cancer could be extended to treat obstructive uropathies. This evidence concerns the gene NKX3-1 and prostate carcinoma.